Results from a Phase II Trial of PRM-151 and a Pilot Study of Imetelstat for Patients with Primary and Secondary Myelofibrosis


Results from a Phase II Trial of PRM-151 and a Pilot Study of Imetelstat for Patients with Primary and Secondary Myelofibrosis
Slides from presentations at ASH 2014 and transcribed comments from a recent interview with Jorge E Cortes, MD (1/14/15)
Verstovsek S et al. Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results. Proc ASH 2014;Abstract 713.

Tefferi A et al. Imetelstat, a telomerase inhibitor, therapy for myelofibrosis: A pilot study. Proc ASH 2014;Abstract 634.

Dr Cortes is DB Lane Cancer Research Distinguished Professor for Leukemia Research and Deputy Chairman and Section Chief of AML and CML in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.